CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.
View Top Employees from CureVacWebsite | http://curevac.com |
Revenue | $91 million |
Funding | $1.8 billion |
Employees | 855 (631 on RocketReach) |
Founded | 2000 |
Address | Friedrich-Miescher-Str. 15, Tübingen, Baden-Württemberg 72076, DE |
Phone | +49 7071 98830 |
Technologies |
JavaScript,
HTML,
PHP
+45 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Manufacturing General, Biopharma, Drug Discovery, Manufacturing, Health Care, Science and Engineering, Therapeutics |
Web Rank | 1 Million |
Keywords | Biopharmaceuticals, Cancer Therapeutics |
Competitors | Acceleron Pharma, BioNTech SE, Dynavax Technologies, Immatics, MacroGenics, Inc. |
SIC | SIC Code 80 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular CureVac employee's phone or email?
The CureVac annual revenue was $91 million in 2024.
Alexander Zehnder is the CEO of CureVac.
631 people are employed at CureVac.
CureVac is based in Tübingen, Baden-Württemberg.
The NAICS codes for CureVac are [3254, 325, 32541, 32].
The SIC codes for CureVac are [80, 283, 28].